Makary’s tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.
Makary’s tenure was marked by internal dysfunction at the FDA, leadership turmoil and mounting backlash from drugmakers and physicians on regulatory decisions.
